Biomarkers show value of studying dementia in Down syndrome.

Biomarkers show value of studying dementia in Down syndrome.
复制标题

生物标志物显示了研究唐氏综合症痴呆的价值。

DOI:
10.1038/s41582-021-00558-w
复制
发表时间:
2021
期刊:
Nature reviews. Neurology
影响因子:
--
通讯作者:
Ledreux,Aurélie
Ledreux,Aurélie
中科院分区:
--
文献类型:
--
作者:
Granholm,Ann-Charlotte;Ledreux,Aurélie

文献摘要

相似文献

超过90%的唐氏综合症患者会发展为阿尔茨海默病,但很少或根本没有接受痴呆症的治疗。衰老和痴呆症的新生物标志物为这一医学弱势群体带来了新的希望,也可以帮助研究人员了解其他人群的痴呆症。
More than 90% of people with Down syndrome develop Alzheimer disease but receive little or no treatment for their dementia. Novel biomarkers of ageing and dementia bring new hope to this medically vulnerable population and can also help researchers understand dementia in other populations.